Phase III study analyzing the effectiveness of dalteparin therapy as intervention in recurrent pregnancy loss.

Trial Profile

Phase III study analyzing the effectiveness of dalteparin therapy as intervention in recurrent pregnancy loss.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2015

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Pregnancy complications; Spontaneous abortion; Thrombosis
  • Focus Therapeutic Use
  • Acronyms ETHIGII
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jul 2007 The expected completion date for this trial is now 1 Jan 2011.
    • 24 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top